- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Telmisartan use linked to reduced risk of Alzheimer's disease and dementia
U.S.A.: According to a study published in the journal, Alzheimer's & Dementia, moderate/high telmisartan exposure was substantially related with a decreased incidence of AD and dementia among African Americans.
Alzheimer's disease (AD) is a neurological ailment that affects a significant number of people and progresses over time. Telmisartan is the only angiotensin II receptor blocker with positive anti-diabetic and renal function effects, which reduces the risk of AD in AAs.
"An important field that could enhance the lives of a wide range of patients is the investigation of race-specific reactions to medicine. Therefore, it is critical to pinpoint the racial impacts of medications using sizable real-world patient datasets and genetic information from people with a variety of ethnic backgrounds," Feixiong Cheng and team stated.
The connection between telmisartan exposure and the course of Alzheimer's disease (AD) was the subject of the authors' investigation.
In order to evaluate potential causal links between AD and telmisartan's target, they carried out race-conscious pharmacoepidemiologic investigations on 5.62 million older people (age 60). They also did Mendelian randomization (MR) analysis on a sizable amount of ethnically diverse genetic data.
Major highlights of the study:
- When AAs were compared to low/no telmisartan exposure, there was a substantial reduction in the incidence of AD (hazard ratio [HR] = 0.77, 95% CI: 0.65-0.91, p-value = 0.0022), but not in non-Hispanic EAs (HR = 0.97, 95% CI: 0.89-1.05, p-value = 0.4110).
- The average hypertension daily dosage and telmisartan's medication possession ratio (MPR) were found to be substantially linked with a stronger reduction in the prevalence of AD and dementia in AAs by sensitivity and sex/age-stratified patient subgroup analyses.
- They discovered AA-specific positive benefits of telmisartan for AD using MR analysis from large genome-wide association studies (GWAS) (over 2 million participants) across AD, hypertension, and diabetes.
The researchers concluded that Telmisartan's favorable benefits on anti-hypertensive, anti-diabetic, and kidney protection may be able to account for its AA-specific therapeutic effects in AD.
REFERENCE
Zhang, P, Hou, Y, Tu, W, et al. Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans. Alzheimer's Dement. 2022; 1- 12. https://doi.org/10.1002/alz.12819
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751